NewEdge Wealth LLC Buys 1,569 Shares of Cencora, Inc. $COR

NewEdge Wealth LLC grew its stake in shares of Cencora, Inc. (NYSE:COR) by 86.4% in the third quarter, according to the company in its most recent filing with the SEC. The firm owned 3,384 shares of the company’s stock after acquiring an additional 1,569 shares during the quarter. NewEdge Wealth LLC’s holdings in Cencora were worth $1,058,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of COR. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Cencora by 13.0% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 48,270 shares of the company’s stock worth $15,086,000 after buying an additional 5,543 shares during the last quarter. Acadian Asset Management LLC raised its stake in Cencora by 947.5% during the second quarter. Acadian Asset Management LLC now owns 257,082 shares of the company’s stock worth $77,069,000 after acquiring an additional 232,539 shares in the last quarter. Mediolanum International Funds Ltd lifted its holdings in shares of Cencora by 133.0% in the third quarter. Mediolanum International Funds Ltd now owns 56,293 shares of the company’s stock worth $17,342,000 after acquiring an additional 32,138 shares during the last quarter. Rhumbline Advisers boosted its stake in shares of Cencora by 4.0% in the 3rd quarter. Rhumbline Advisers now owns 430,150 shares of the company’s stock valued at $134,435,000 after purchasing an additional 16,539 shares in the last quarter. Finally, Advisors Asset Management Inc. grew its holdings in shares of Cencora by 40.3% during the 3rd quarter. Advisors Asset Management Inc. now owns 17,302 shares of the company’s stock valued at $5,407,000 after purchasing an additional 4,973 shares during the last quarter. Institutional investors own 97.52% of the company’s stock.

Wall Street Analysts Forecast Growth

COR has been the subject of several research reports. Robert W. Baird set a $415.00 price objective on shares of Cencora in a research note on Tuesday, January 13th. UBS Group increased their price target on Cencora from $380.00 to $415.00 and gave the company a “buy” rating in a research note on Friday, November 7th. Wall Street Zen lowered Cencora from a “buy” rating to a “hold” rating in a research report on Friday, November 28th. Mizuho upped their target price on Cencora from $340.00 to $380.00 and gave the stock an “outperform” rating in a report on Thursday, November 6th. Finally, Bank of America cut their price target on Cencora from $380.00 to $360.00 and set a “neutral” rating on the stock in a research note on Monday, January 5th. Eleven research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $399.00.

Insider Buying and Selling

In other news, EVP Silvana Battaglia sold 1,677 shares of Cencora stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $345.00, for a total value of $578,565.00. Following the completion of the transaction, the executive vice president directly owned 18,796 shares of the company’s stock, valued at approximately $6,484,620. This trade represents a 8.19% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Robert P. Mauch sold 5,096 shares of the company’s stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of $354.73, for a total value of $1,807,704.08. Following the sale, the chief executive officer owned 66,726 shares in the company, valued at approximately $23,669,713.98. The trade was a 7.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 15,220 shares of company stock valued at $5,282,867 over the last quarter. Insiders own 0.38% of the company’s stock.

Cencora Trading Up 0.4%

NYSE COR opened at $360.70 on Monday. The firm has a market capitalization of $70.17 billion, a PE ratio of 43.35, a price-to-earnings-growth ratio of 1.68 and a beta of 0.68. The business’s 50-day moving average price is $349.41 and its two-hundred day moving average price is $331.39. The company has a current ratio of 0.92, a quick ratio of 0.51 and a debt-to-equity ratio of 3.62. Cencora, Inc. has a 12 month low of $240.72 and a 12 month high of $377.54.

Cencora (NYSE:COR) last issued its quarterly earnings data on Wednesday, February 4th. The company reported $4.08 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.04 by $0.04. Cencora had a return on equity of 176.54% and a net margin of 0.50%.The company had revenue of $85.93 billion during the quarter, compared to the consensus estimate of $86.12 billion. During the same period last year, the company earned $3.73 earnings per share. The firm’s revenue was up 5.5% compared to the same quarter last year. On average, analysts expect that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 2nd. Stockholders of record on Friday, February 13th will be given a dividend of $0.60 per share. The ex-dividend date is Friday, February 13th. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. Cencora’s dividend payout ratio is 28.85%.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.